1. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47–59.
2. Arcamone F. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture. Cancer Res. 1985;45:5995–9.
3. Arlin ZA. Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia. Cancer Treat Rep. 1983;67:967–70.
4. Baguley BC. The development of new DNA intercalating anti-cancer drugs. In: Watanabe HS, editors. Horizons in cancer research. New York: Nova Publishers; 2012. p. 47–65.
5. Baguley BC, Ferguson LR. Mutagenic properties of topoisomerase-targeted drugs. Biochim Biophys Acta. 1998;1400:213–22.